JANX Stock Forecast 2025-2026
Distance to JANX Price Targets
JANX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Janux (JANX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on JANX and similar high-potential opportunities.
Latest JANX Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, JANX has a bullish consensus with a median price target of $83.00 (ranging from $25.00 to $200.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $29.69, the median forecast implies a 179.6% upside. This outlook is supported by 12 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Josh Schimmer at Cantor Fitzgerald, projecting a 573.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
JANX Analyst Ratings
JANX Price Target Range
Latest JANX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for JANX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 3, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $70.00 |
| Feb 28, 2025 | Scotiabank | George Farmer | Sector Perform | Maintains | $41.00 |
| Dec 11, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $200.00 |
| Dec 4, 2024 | Scotiabank | George Farmer | Sector Perform | Maintains | $62.00 |
| Dec 3, 2024 | Stifel | Bradley Canino | Buy | Maintains | $115.00 |
| Dec 3, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $70.00 |
| Dec 3, 2024 | Leerink Partners | Jeffrey La Rosa | Outperform | Maintains | $91.00 |
| Nov 22, 2024 | Leerink Partners | Jeffrey La Rosa | Outperform | Initiates | $79.00 |
| Nov 7, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $100.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $63.00 |
| Oct 24, 2024 | UBS | David Dai | Buy | Initiates | $69.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $100.00 |
| Sep 6, 2024 | Stifel | Bradley Canino | Buy | Initiates | $70.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $63.00 |
| Aug 9, 2024 | Scotiabank | George Farmer | Sector Perform | Maintains | $42.00 |
| Aug 8, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $74.00 |
| Aug 8, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $100.00 |
| May 30, 2024 | Scotiabank | George Farmer | Sector Perform | Initiates | $47.00 |
| May 13, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $63.00 |
| May 9, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $100.00 |
Janux Therapeutics Inc. (JANX) Competitors
The following stocks are similar to Janux based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Janux Therapeutics Inc. (JANX) Financial Data
Janux Therapeutics Inc. has a market capitalization of $1.75B with a P/E ratio of 0.0x. The company generates $10.59M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -933.6% and return on equity of -10.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Janux Therapeutics Inc. (JANX) Business Model
About Janux Therapeutics Inc.
Develops novel immunotherapies for cancer treatment.
Janux Therapeutics Inc. generates revenue through the development and commercialization of its proprietary immunotherapy technologies, specifically the Tumor Activated T Cell Engager (TRACTr) platform. By targeting cancer cells directly while minimizing systemic exposure, the company aims to enhance treatment efficacy and safety, positioning itself strategically within the biopharmaceutical sector focused on immuno-oncology.
The company is headquartered in La Jolla, California, and is dedicated to addressing unmet medical needs in cancer treatment. As it advances its innovative therapies, Janux Therapeutics holds potential for significant contributions to personalized and targeted cancer therapies, which may lead to improved patient outcomes globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
81
CEO
Dr. David Alan Campbell Ph.D.
Country
United States
IPO Year
2021
Website
www.januxrx.comJanux Therapeutics Inc. (JANX) Latest News & Analysis
Janux Therapeutics' JANX007 shows promising early prostate cancer results. The company has $1.03 billion in cash, reducing dilution risk. Recent stock pullback offers a potential buying opportunity.
Janux Therapeutics' promising prostate cancer drug and strong cash position reduce dilution risk, making the recent stock pullback a potential buying opportunity amid market weakness.
Recent activity in the biotechnology sector includes multiple initial public offerings and significant insider purchases, indicating increased investor interest.
Increased IPO activity and insider buying in biotechnology indicate growing market confidence, potentially signaling investment opportunities and sector momentum.
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
1 month agoJanux Therapeutics (Nasdaq: JANX) reported Q4 and full-year 2024 financial results, highlighting progress in its immunotherapy pipeline, including TRACTr and TRACIr platforms.
Janux Therapeutics' strong financial results and advancements in immunotherapy technology could indicate growth potential, impacting stock valuation and investor interest.
Janux Therapeutics has promoted Zachariah McIver, D.O., Ph.D., to Chief Medical Officer, which may impact the company's future strategic direction and medical initiatives.
Zachariah McIver's promotion may signal strategic shifts in Janux Therapeutics' clinical development, impacting drug pipeline progress and investor confidence.
Janux Therapeutics' JANX007 shows high efficacy in Phase 1 trials for prostate cancer. The company has $658.1M in liquid assets, no debt, and is seen as a top biotech buyout candidate for 2025.
Janux Therapeutics' positive trial results and strong financial position enhance its attractiveness for investment, while its innovative approach could lead to significant market opportunities and potential buyout interest.
Best-Performing Stocks Of 2024
3 months agoIn 2024, the top 20 performing stocks among the Russell 3,000 members have been identified, highlighting potential investment opportunities.
Identifying the top-performing stocks in the Russell 3,000 offers insights into market trends, sector performance, and potential investment opportunities for portfolio growth.
Frequently Asked Questions About JANX Stock
What is Janux Therapeutics Inc.'s (JANX) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Janux Therapeutics Inc. (JANX) has a median price target of $83.00. The highest price target is $200.00 and the lowest is $25.00.
Is JANX stock a good investment in 2025?
According to current analyst ratings, JANX has 12 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $29.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for JANX stock?
Wall Street analysts predict JANX stock could reach $83.00 in the next 12 months. This represents a 179.6% increase from the current price of $29.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Janux Therapeutics Inc.'s business model?
Janux Therapeutics Inc. generates revenue through the development and commercialization of its proprietary immunotherapy technologies, specifically the Tumor Activated T Cell Engager (TRACTr) platform. By targeting cancer cells directly while minimizing systemic exposure, the company aims to enhance treatment efficacy and safety, positioning itself strategically within the biopharmaceutical sector focused on immuno-oncology.
What is the highest forecasted price for JANX Janux Therapeutics Inc.?
The highest price target for JANX is $200.00 from Josh Schimmer at Cantor Fitzgerald, which represents a 573.6% increase from the current price of $29.69.
What is the lowest forecasted price for JANX Janux Therapeutics Inc.?
The lowest price target for JANX is $25.00 from at , which represents a -15.8% decrease from the current price of $29.69.
What is the overall JANX consensus from analysts for Janux Therapeutics Inc.?
The overall analyst consensus for JANX is bullish. Out of 14 Wall Street analysts, 12 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $83.00.
How accurate are JANX stock price projections?
Stock price projections, including those for Janux Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.